Stemcelline Vial - WJ- Exo

Introduction

100 billion in 2ml vial

One of the subpopulations of EVs is referred to as “exosomes.” Apoptotic bodies and microvesicles/shedding particles are the other two subpopulations (both larger than 100 nm). Exosomes are created when late endosomes, or so-called multivesicular structures, sprout intraluminal vesicles (ILVs) in their luminal region (MVBs). Once the MVBs have been incorporated into the cellular membrane, the ILVs are subsequently released as exosomes.

Because of their wide availability, low cost, and simple, non-invasive isolation process, WJ-MSCs offer a lot of potential for allogeneic and autologous transplantation.

Additionally, WJ-MSCs are highly proliferative, nontumorigenic, and do not result in teratomas following transplantation. WJ-MSCs are thus ideal for regenerative medicine. Mesenchymal stem cells use paracrine mediators like exosomes to restore tissue injury.

One of the paracrine mediators generated from MSCs is the exosome. They are microscopic, membrane-bound vesicles with a size range of 30–100 nm that is secreted by several cell types. They also transport cargo to the intended tissues, including proteins, mRNA, and non-coding RNA.

How do we prepare Stemcelline vial- WJ-Exo?

We examined how WJ-MSCs-derived exosomes affected the expression of fibrotic genes such as α-smooth muscle actin, E-cadherin, collagen 1, and Smad2/3 phosphorylation. Additionally, we looked at whether pretreating WJ-MSCs with various TGF doses altered the anti-fibrotic characteristics of their exosomes.

How is the Stemcelline vial different?

MSCs can be extracted from Wharton’s jelly and used in clinical settings. There are no ethical issues with employing these MSCs, and they have more stem-like characteristics than other tissue-derived MSCs.

It appears that Wharton jelly-derived cells might be great sources for the therapy of this illness in the future, based on preclinical research using mesenchymal stem cells produced from various sources in the pulmonary fibrosis model.

By doing more clinical testing studies with WJ-MSC, it will be feasible to provide a clear view on the future management of pulmonary fibrosis. While waiting for a new therapeutic strategy to be developed, patients with pulmonary fibrosis may benefit from choosing the right cell dosage, number of injections, injection technique, and precise procedures for cell isolation, culture, and proliferation.

Note:- FOR RESEARCH PURPOSE ONLY.